**SUPPLEMENTARY TABLE 2.** **Coverage with influenza, COVID-19, and respiratory syncytial virus (RSV) vaccines among adults,\* by Health and Human Services region — National Immunization Survey-Adult COVID Module, United States, November 9, 2024**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **HHS Region†** | **Influenza** | **COVID-19** | **RSV (adults aged ≥75 years)** | **RSV (adults aged 60–74 years, increased risk)** |
| **Cumulative n (unweighted)** | **% vaccinated****(95% CI)§** | **Cumulative n (unweighted)** | **% vaccinated****(95% CI)§** | **Cumulative n (unweighted)** | **% vaccinated****(95% CI)§** | **Cumulative n (unweighted)** | **% vaccinated****(95% CI)§** |
| Region 1 | 13,649 | 43.4(39.5–47.3) | 11,519 | 24.8(21.9–27.7) | 8,229 | 43.5(38.9–48.1) | 1,017 | 32.6(25.0–40.2) |
| Region 2 | 11,495 | 33.5(30.5–36.5) | 9,255 | 15.5(13.6–17.4) | 6,208 | 31.6(27.1–36.0) | 699 | 22.9(16.8–29.1) |
| Region 3 | 21,796 | 39.6(36.7–42.5) | 18,364 | 20.3(18.1–22.5) | 12,246 | 41.3(38.1–44.5) | 1,500 | 30.8(25.6–36.0) |
| Region 4 | 15,948 | 28.7(25.5–31.9) | 12,832 | 13.4(11.1–15.8) | 10,613 | 34.3(31.4–37.2) | 969 | 35.4(25.2–45.5) |
| Region 5 | 15,425 | 35.7(32.1–39.3) | 12,546 | 20.5(17.9–23.1) | 8,453 | 46.5(41.0–51.9) | 946 | 35.5(29.2–41.9) |
| Region 6 | 19,958 | 32.2(27.9–36.4) | 16,318 | 13.9(10.7–17.1) | 10,597 | 32.9(28.9–36.8) | 1,248 | 31.9(21.4–42.4) |
| Region 7 | 5,975 | 40.1(33.9–46.4) | 4,278 | 20.1(15.3–24.8) | 3,404 | 43.0(36.5–49.5) | 322 | 28.0(16.4–39.6) |
| Region 8 | 14,145 | 37.0(30.8–43.3) | 12,365 | 19.1(14.7–23.5) | 8,284 | 42.7(38.9–46.5) | 983 | 43.4(32.2–54.6) |
| Region 9 | 11,381 | 39.2(33.3–45.1) | 9,261 | 21.7(17.7–25.8) | 7,423 | 44.4(36.6–52.2) | 642 | 25.5(19.2–31.8) |
| Region 10 | 6,423 | 33.0(27.3–38.7) | 5,302 | 21.6(17.0–26.1) | 4,109 | 52.7(38.5–66.8) | 341 | 37.2(30.9–43.5) |

**Abbreviations:** HHS = Department of Health and Human Services; RSV = respiratory syncytial virus.

\* Estimates presented for influenza and COVID-19 vaccination are among adults aged ≥18 years. Estimates for RSV vaccination are among adults aged ≥75 years and aged 60–74 years who are at increased risk for severe RSV disease. Estimates of vaccination coverage were calculated for November 3–9, 2024 using a nondecreasing composite estimation procedure that uses data from all completed interviews during August 18, 2024–November 9, 2024 (Influenza vaccination among persons aged ≥18 years, N = 136,195); September 1, 2024– November 9, 2024 (COVID-19 vaccination among persons aged ≥18 years, N = 112,040); September 24, 2023– November 9, 2024 (RSV vaccination among persons aged ≥75 years, N = 79,566); and August 25, 2024– November 9, 2024 (RSV vaccination among persons aged 60–74 years, at increased risk for severe RSV disease, N = 8,667). A respondent was considered to be at increased risk for severe RSV disease based on the criteria defined in https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm#B1\_down: chronic lung diseases, diabetes with insulin use, heart conditions, immunocompromised state, solid organ or blood stem cell transplant (including bone marrow transplant), cancer, liver disease, sickle cell disease or thalassemia, or currently lives in a nursing home.

† HHS Regions: (1) Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; (2) New Jersey, New York, Puerto Rico; (3) Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; (4) Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; (5) Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; (6) Arkansas, Louisiana, New Mexico, Oklahoma, Texas; (7) Iowa, Kansas, Missouri, Nebraska; (8) Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; (9) Arizona, California, Hawaii, Nevada; (10) Alaska, Idaho, Oregon, Washington.

§ Weighted percentage.